SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a non-exclusive license agreement with Pfizer for its Matrix-M adjuvant, providing significant validation for the technology. This deal, building on previous collaborations, is driving community excitement and fueling discussions about the adjuvant's potential applications and the company's future partnerships amidst notable short interest.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following positive regulatory advancements for its ANKTIVA therapy, with the FDA outlining a path to resubmission for papillary bladder cancer that requires no new clinical trials. This news, combined with recent international approvals, is fueling strong community sentiment around the potential for a "cancer cure" and intense discussions anticipating a substantial short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to heightened geopolitical tensions, specifically former President Trump's recent tariff threats against NATO allies over Greenland and an anticipated Supreme Court ruling on presidential tariff authority. This has sparked a fierce debate among investors, with some advocating to "buy the dip" and anticipating a rapid "Taco Trade" rebound, while others warn of a significant market correction. Adding to the volatility are concerns surrounding Japan's bond market instability, creating a complex and uncertain trading environment.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point among investors, primarily driven by its upcoming earnings report and the proposed all-cash acquisition of Warner Bros. Discovery assets, which has sparked a debate over potential growth versus debt concerns. The community is closely watching for strong ad-tier performance and subscriber metrics, particularly after a previous tax-related earnings miss, with sentiment split on whether recent oversold conditions signal a significant rebound or continued volatility.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is driving significant conversation as escalating US-EU trade tensions, particularly over Greenland and proposed tariffs, spark widespread market uncertainty and a risk-off shift. The community is sharply divided, with intense debate over whether current volatility signals a deeper correction or presents a key buying opportunity amidst ongoing institutional interest and broader macroeconomic shifts.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is trending strongly as renewed geopolitical tensions, including recent tariff threats concerning European countries over Greenland, fuel a broad flight to safety. The community views gold as a crucial hedge against eroding fiat currency confidence and economic instability, driving prices to consistent new highs. Many are discussing significant further appreciation as these global uncertainties persist.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin ($APP) is experiencing significant volatility and a notable price decline following a new short report alleging the company's involvement in money laundering. This report has sparked intense debate among investors, with many attributing the drop to market manipulation and viewing it as a buying opportunity, while others express concern over the serious accusations despite recent bullish analyst upgrades.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as former President Trump's renewed threats of tariffs on NATO allies, particularly over the acquisition of Greenland, spark fears of a trade war with Europe. This escalating geopolitical tension is causing widespread market jitters and calls for caution, though many investors are also discussing it as a potential "buy the dip" opportunity for growth stocks.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, with community discussions highlighting its strong efficacy in treatment-resistant patients. Investors are actively debating the potential for this novel oral ITK inhibitor to disrupt the significant atopic dermatitis market, fueling speculation of future partnerships or an acquisition and validating its broader immune-modulating platform.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share.</li><li>The split will reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million</li><li>Total authorized share count will remain unchanged at 500 million.</li></ul>&nbsp;Shares of Moleculin Biotech Inc. (MBRX) plunged over 25% on Wednesday to their lowest in five months, after the company announced a reverse stock split.Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective Dec. 1, 2025, following which, the company’s shares will begin trading on a post-split basis on the Nasdaq Capital Market under the existing ticker symbol MBRX.<h2 class="st-heading-2">The Reverse Split</h2>The reverse split will consolidate every 25 shares of outstanding common stock into a single share, while maintaining the current par value of $0.001 per share. Moleculin added that it will not issue fractional shares, and any shareholder entitled to one will receive a cash payment to replace the fractional amount.The move will significantly reduce the number of outstanding shares from roughly 51.7 million to about 2.1 million, while the total authorized share count will remain unchanged at 500 million.Companies often use reverse splits to avoid being delisted, as primary exchanges require stocks to maintain a minimum price of $1.00. If a stock trades below this level for 30 straight sessions, the company receives a deficiency notice and is given a limited window to lift the share price. A reverse stock split can help the firm regain compliance and keep its listing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/MBRX">MBRX</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.&nbsp;&nbsp;One user believes a share repurchase could go some way in boosting confidence.<stembedurl>https://stocktwits.com/Healthpro/message/637501819</stembedurl>MBRX stock has fallen more than 80% so far this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-de-stock-falling-today/cL538QhREWX">Why Is DE Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did MBRX Stock Plummet Over 25% Today?

Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.

Equity

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Current Price	$4.16
Prev Close	$4.27
Open	$4.30
Dividend Yield	0.00%
50-Day Moving Average	$6.71
Beta	0.88
Avg. Volume	585,315.95
PE Ratio	-0.07

52-Week High	$91.25
52-Week Low	$3.13
Market Capitalization	$12.81M
EPS (Annual)	-$158.02
Price to Book	-0.31
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBRX News

MBRXMoleculin Biotech Inc